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ABSTRACT
The original histopathologic description of chronic graft-versus-host disease (CGVHD) of the gastrointestinal (GI)
tract was from autopsy series. There is little information on the evaluation of living patients with CGVHD and GI
symptoms. We reviewed data on 40 consecutive patients with CGVHD and persistent GI symptoms who underwent
endoscopic examinations. The diagnosis of CGVHD in these 40 patients was made on the basis of clinical criteria and
confirmed by histology of other involved organs in 70%. Patients had progressive (in 19 patients, or 48%), quiescent
(in 11, or 27%) or de novo–type (in 10, or 25%) onset of their CGVHD. Four groups were defined based on the
following histologic criteria: (1) consistent with acute GI GVHD if there was marked apoptosis with or without
cryptitis, (2) suggestive of acute GI GVHD if there was scattered apoptosis with or without cryptitis, (3) suggestive
of chronic GI GVHD if there were at least 2 histologic indicators of chronicity such as fibrosis and significant crypt
distortion, and (4) no histologic evidence of GVHD. Results of microbiologic, radiologic, and malabsorption studies,
if performed, were also retrieved. Median time from diagnosis of CGVHD to GI endoscopy was 4.5 months (0-109
months). The major GI symptoms at the time of endoscopy were diarrhea, abdominal pain/cramping, nausea/
vomiting, weight loss, dysphagia, and early satiety. The endoscopic examination was nonspecific for the diagnosis of
GI GVHD except for diffuse mucosal sloughing. Based on the histologic criteria in 22 patients with biopsies, 13 cases
(59%) were considered to have acute GI GVHD, and 3 cases (14%) were felt to show possible chronic GI GVHD;
changes of both acute and chronic GVHD were seen in 6 (27%) cases. GI dysmotility was diagnosed in 7 (18%)
patients, including 2 of the patients who had histologic changes suggestive of chronic GVHD. Other causes of the GI
symptoms included infection, drug side effect, and malabsorption. In conclusion, GI involvement by acute GVHD
appears to be a major cause of persistent GI symptoms in patients with chronic GVHD. An isolated form of chronic
GI GVHD confirmed by histology is an uncommon phenomenon in the actual clinical setting.
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INTRODUCTION
Since the use of modern immunosuppressive treatment reg-
imens began, there has been a considerable shift in the pattern
and clinical manifestations of chronic graft-versus-host disease
(CGVHD). Many of the severe manifestations of the disease
reported in the initial description of CGVHD [1,2], such as
nasal mucosal CGVHD, arthralgia/arthritis, serositis, myositis,
and cardiopulmonary involvement, are rarely seen. One of the
controversial sites of involvement in CGVHD is the gastroin-
testinal (GI) tract. Although intestinal involvement in patients
with untreated CGVHDwas described in early studies [1,2], this
is now rarely seen with the reported symptoms and radiographic
and histologic ﬁndings.
In clinical practice, however, physicians are often faced with
CGVHD patients who also have a variety of GI symptoms such
as esophageal reﬂux, dysphagia, bloating, weight loss, and diar-
rhea [3,4]. These GI symptoms are often attributed to gastro-
intestinal involvement by chronic GVHD. However, there has
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been no consensus as to the clinical symptoms or histologic
ﬁndings of GI CGVHD. Although rectal biopsy is known to
have diagnostic utility, using the crypt abscess as a major diag-
nostic criterion in acute GVHD [2], there is no established role
of endoscopic evaluation and mucosal biopsy in the diagnosis of
chronic GI GVHD. The histologic changes of chronic GI
GVHD (ie, ﬁbrosis, mononuclear cell inﬁltration, and sclerosis
and hyalinization of small venules) are mainly conﬁned to sub-
mucosa and subserosa [5,6]. There is a need to improve the
current understanding of GI involvement in CGVHD. In this
case series, we describe our clinical ﬁndings in a group of
patients with chronic GVHD whose GI symptoms required
endoscopic evaluation.
PATIENTS AND METHODS
Data on 40 consecutive patients with CGVHD who under-
went 42 upper and/or lower GI endoscopies because of persis-
tent GI symptoms were reviewed. Patients included in this study
were selected based on their history of endoscopic evaluation
and the availability of GI pathology reports between 1987 and
2000. Endoscopic examinations of 28 cases were performed by a
single gastroenterologist at the Johns Hopkins Hospital. The
remaining 14 examinations were done by other gastroenterolo-
gists. The site of the GI tract to be examined by endoscopy was
determined primarily by the patients’ main symptoms. If a
patient had only diarrhea, upper GI endoscopy was not included
in the evaluation process. If a patient had both upper and lower
GI symptoms, both sites of the GI tract were examined. Results
of other diagnostic evaluations including microbiologic, radio-
logic, and malabsorption studies, if performed, were retrieved.
Six additional patients were not included in the study because of
inadequate biopsies (lacking submucosa or adequate tissue for
interpretation). Sixteen (40%) patients underwent transplanta-
tion in outside institutions and were referred to Johns Hopkins
for the management of chronic GVHD. All patients were diag-
nosed with chronic GVHD of the skin, eye, mouth, or liver
based on established clinical and histologic criteria [1,7-9] prior
to (n29) or at the onset of (n11) GI symptoms. In 28 patients
(70%), the diagnosis of CGVHD had been conﬁrmed by histo-
logic evaluation of the skin or liver, or both.
All biopsy slides had been previously read and reported by
GI pathologists at Johns Hopkins. One third of these slides were
from outside institutions. For this particular study, the pathol-
ogy was reviewed blindly by a different GI pathologist (M. T.).
The pathology was reviewed without clinical information to as
much as possible prevent bias in the interpretation. Four groups
were deﬁned based on histologic criteria: (1) features consistent
with acute GI GVHD if there was marked apoptosis with or
without cryptitis (Figure 1A,B); (2) features suggestive of acute
GVHD such as scattered apoptosis with or without cryptitis; (3)
features suggestive of chronic GI GVHD if there were at least 2
histologic indicators for chronicity, such as ﬁbrosis, signiﬁcant
mucosal architectural (crypt) distortion (Figure 1C), increased
lymphocyte/plasma cell inﬁltration in the lamina propria, and
the presence of Paneth cell metaplasia (deﬁned by Paneth cells
in the left colon and/or rectum, which are normally present in
the right and transverse colon) (Figure 1D) or pyloric metapla-
sia; and (4) no evidence of GVHD. Other diagnostic evaluations
included microbiologic studies, a 24-hour fecal fat excretion,
computed tomography and upper GI series, cineesophagogram.
The outcome of the GI symptoms and related ﬁndings after the
endoscopic evaluation were noted.
In general, occasional or scattered apoptic bodies would
equate to 1 to 2 apoptotic bodies per 5 crypts. In many of the
specimens, a spectrum of changes between normal mucosa (no
GVHD) and cryptitis/crypt abscess was reported. Invasion of
crypt epithelium by neutrophils, or cryptitis, was used as an
indicator of acute inﬂammation.
The crypt abscess was deﬁned as a crypt that is dilated and
contains necrotic cellular debris with inﬂammatory cells (neu-
trophils, eosinophils, or mononuclear cells) in the lumen. These
features, in combination with apoptosis, were consistent with
acute GI GVHD. When these features were present to a lesser
degree, we categorized this as suggestive of acute GVHD.
There were various histologic features indicating chronicity or
chronic inﬂammation, which included ﬁbrosis or scarring, lym-
phoplasmacytic inﬁltration in lamina propria, architectural
(crypt) distortion or loss, submucosal ﬁbrosis, Paneth cell meta-
plasia, pyloric metaplasia, and inﬂammatory polyp formation.
Architectural distortion was deﬁned by forked crypts and/or
Paneth cell metaplasia (left colon and rectum), crypt loss and/or
crypt shortfall (crypts no longer extend to muscularis mucosae),
gland loss (if biopsy from the body) and/or intestinal metaplasia
(body or antrum), villous blunting, pyloric metaplasia, and gland
distortion (duodenum). Chronic Helicobacter pylori infection also
causes intestinal metaplasia, and H pylori infection was therefore
sought. Two patients were found to have H pylori infection.
RESULTS
Forty consecutive patients with chronic GVHD underwent
a total of 42 upper (n14), lower (n15) and both upper and
lower (n13) GI endoscopic examinations between January
1987 and November 2000. Demographic features and bone
marrow transplantation (BMT) and GVHD data are summa-
rized in Table 1. There were 27 male patients and 13 female
patients, with a median age of 31.5 years (range 1 to 52).
Thirty-one patients developed acute GVHD following the
transplantation with 80% of those having grade 2-4 acute
GVHD. Of those with GVHD, 10 (32%) patients had gut
involvement. Of the 10 with acute GI GVHD, 5 had persistent
GI symptoms at the time of referral and evaluation for chronic
GVHD. For the entire group, the median time from the trans-
plantation to diagnosis of CGVHD was 5 months (2-21 mos).
The diagnosis of chronic GVHD was made before day 100 in
9 (22%) patients. Nineteen (48%) patients had progressive onset
of chronic GVHD, 11 (27%) had quiescent onset, and 10 (25%)
had de novo–type onset.
The major GI symptoms at the time of endoscopic evalua-
tion included diarrhea (74%), abdominal pain/cramping (45%),
nausea/vomiting (33%), and weight loss (19%). The diarrhea
was severe ( 1 liter or 5 times/day) in 48% of the patients.
Median time from diagnosis of CGVHD to GI endoscopy was
4.5 months (0-109 months). Eleven patients (26%) had their GI
evaluation done at the time of their initial diagnosis of chronic
GVHD (Table 2).
The patients were subdivided by the time after diagnosis of
CGVHD. The clinical presentation and histologic ﬁndings in
the 25 patients who developed GI symptoms within 1 year of
diagnosis of CGVHD were different from the late-onset ( 1
year) group. Many of these patients had progressive onset of
GI Involvement in cGVHD
47BB&MT
CGVHD with persistent symptoms of acute GI GVHD. Thus
symptoms of diarrhea, abdominal pain/cramps, and nausea/
vomiting were more common in this early-onset group. All 22
patients who had acute GVHD features in biopsy samples were
in this early-onset group. Also, all 7 patients who had GI infec-
tions (Clostridium difﬁcile [n2], CMV [n1], bacterial over-
growth [n2] and Helicobacter pylori [n2]) were in this early-
onset group. Not surprisingly, the 12 patients who expired
during the course of follow-up were in this early-onset group.
In the 15 (35%) patients who underwent endoscopy for GI
symptoms more than 1 year after the diagnosis of chronic
GVHD, chronic diarrhea (n9), weight loss (n6), abdominal
pain (n5), and dysphagia (n4) were the most common GI
symptoms. Histologic ﬁndings of GI GVHD were found in only
3 (20%) patients. The most frequent diagnoses in this subgroup
were drug-induced gastritis (33%), GI dysmotility (27%), and
pancreatic insufﬁciency responding to pancreatic enzyme re-
placement therapy (13%). These patients improved their symp-
toms with therapy directed at the underlying cause, such as
discontinuing the drug that was causing the gastritis, starting
pro-motility agents, and replacing pancreatic enzymes.
Except in patients with diffuse mucosal sloughing, there
were no pathognomonic endoscopic ﬁndings for GVHD. Based
on histopathologic criteria we used, 22 (52%) of 42 biopsies
were considered to be consistent with GI involvement by acute
GVHD in 13 (59%), possible chronic GVHD in 3 (14%), and
both in 6 (27%) cases. Characteristics of the 9 cases that had a
component of possible chronic GVHD involvement in the GI
tract are summarized in Table 3.
GI dysmotility, including gastroparesis, esophageal spasm,
and delay in transit time was diagnosed in 7 patients. Four (57%)
were in the late-onset GI GVHD group. Drugs such as myco-
phenolate mofetil, clofazimine, and non-steroidal anti-inﬂam-
matory agents were felt to be the cause of GI symptoms in 6
cases, 5 of which (83%) were in the group of late-onset GI
GVHD.
All patients were managed according to the underlying
cause of GI symptoms. Patients who were diagnosed with active
GVHD of the GI tract were treated with immunosuppression.
Drug-related or infectious causes were treated accordingly.
Overall, the GI symptoms either resolved or improved in 36
cases (86%) with appropriate management.
As of December 2001, 12 of 22 patients who had GI GVHD
expired; 11 of these deaths were due to non-relapse causes.
Prolonged acute GVHD in the intestinal tract was associated
with adverse outcome; all 5 patients in this category died.
Figure 1. Histologic changes of acute and chronic graft-versus-host disease (GVHD) in the colon. A, numerous apoptotic bodies are present in the
crypt epithelium (arrow), consistent with acute GVHD. B, Several crypts are present with marked damage and reactive epithelial changes as well as
neutrophils in the lumen of the central crypt (cryptitis), changes consistent with acute GVHD. C, Marked crypt distortion and loss is present in this
biopsy specimen, suggesting chronic GVHD. D, Paneth cell metaplasia (arrows) is another marker on chronic inﬂammatory disease that is suggestive
of chronic GVHD in the right clinicopathologic setting.
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DISCUSSION
Our data in this study suggest that persistent GI symptoms
occurring during the course of chronic GVHD are due to
GVHD itself in 55% of the cases, as evaluated with endoscopy.
However, the histopathologic changes were consistent with
acute GVHD in the majority of patients who had biopsy-proven
GVHD. All 5 patients with persistent acute GI GVHD died,
although the number of cases included in this series did not
allow us to perform a meaningful risk factor analysis,
In the present study, we used a stringent deﬁnition of
chronic GI GVHD to avoid introducing bias and inter-observer
variation. The most important diagnostic criterion for the evi-
dence of acute GVHD in the GI tract is the demonstration of
epithelial single cell necrosis (apoptosis), which may be accom-
panied by increased inﬂammation (cryptitis) and reactive epi-
thelial changes or loss [5,10]. Our criteria for diagnosing acute
GI GVHD in patients with chronic GVHD conform to this
deﬁnition. In contrast, many transplant physicians categorize
GVHD by day post-BMT rather than by biologic and histologic
changes. GVHD is usually called chronic if it is diagnosed after
day 100 of transplant. In our cohort, the diagnosis of chronic
GVHD was made before day 100 in 9 (22%) patients based on
the clinical features, including lichenoid skin rash; lichenoid
changes in oral mucosa; development of dry mouth and/or dry
eye; and persistent cholestatic liver abnormalities plus histologic
criteria of chronic GVHD on skin, oral, and liver biopsies,
which include sclerosis, epidermal keratosis, vacualization, li-
Table 2. Evaluation of GI Symptoms
GI symptoms (n  42)
Diarrhea 31 (74%)
Abdominal pain/cramps 19 (45%)
Nausea/vomiting 14 (33%)
Weight loss 8 (19%)
GI bleeding 5 (12%)
Dysphagia 5 (12%)
Early satiety/fullness 5 (12%)
Heartburn 2 (5%)
Failure to thrive 1 (2%)
Partial intestinal obstruction 1 (2%)
Median time from diagnosis of CGVHD to GI
biopsy, range (n  42) 4.5 months (0-109)
Biopsy at initial diagnosis of CGVHD 11 patients (26%)
Biopsy within 1 month after diagnosis of
CGVHD 17 patients (40%)
Biopsy within 1 year after diagnosis of
CGVHD 30 patients (71%)
Biopsy after 3 years of diagnosis of CGVHD 6 patients (14%)
On systemic immunosuppression at GI
presentation 39 (93%)
Immunosuppressive medication at GI
evaluation (n  39)
Corticosteroid 21 (54%)
Cyclosporine 16 (41%)
Tacrolimus (FK-506) 15 (38%)
Mycophenolate mofetil 10 (26%)
Thalidomide 5 (13%)
Azathioprine 4 (10%)
Daclizumab 2 (5%)
Pentostatin 1 (3%)
GI sites evaluated (n  42)
Colon and rectum 27 (64%)
Small bowel 23 (55%)
Esophagus 16 (38%)
Stomach 13 (31%)
GI biopsy site (n  42)
Upper GI 14 (33%)
Lower GI 15 (36%)
Both upper and lower GI 13 (31%)
Severity of diarrhea (n  31)
Mild (<0.5 L or <3 times/day) 4 (13%)
Moderate (0.5-1.0 L or 3-5 times/day) 12 (39%)
Severe (>1 L or >5 times/day) 15 (48%)
Other diagnostic work-up (positive/all results)
Infectious 7/41
C difficile 2/41
CMV 2/41
Bacterial overgrowth 2/41
H pylori 1/41
CT/GI series (thickened, dilated, featureless
small bowel) 6/8
Cineesophagogram (stricture, dysmotility,
gastroparesis) 5/9
24-hour fecal fat 3/4
Abdominal X-ray (ileus) 1
Surgical exploration (fibrotic gall bladder) 1
CMV indicates cytomegalovirus.
Table 1. Patient Characteristics
Male/female 27/13
Median age, y (range) 31.5 (1-52)
BMT data
Bone marrow was the source of
graft
40 (100%)
Second BMT/DLI/“mini” BMT 1/1/1
Matched-related donor 33 (82%)
Matched-unrelated donor 5 (12%)
Mismatched-related donor 2 (5%)
Cytoreductive therapy
Cyclophosphamide and TBI 19 (48%)
Busulfan and cyclophosphamide 17 (42%)
Others 4 (10%)
Acute GVHD 31 (77%)
Grade 1 6 (20%)
Grade 2 24 (77%)
Grade 3-4 1 (3%)
Skin involvement 30 (97%)
Liver involvement 11 (35%)
Gut involvement 10 (32%)
Diagnosis of CGVHD Between 1/1987 and 11/2000
Before 1995 18
1995 or later 22
Median time to diagnosis of CGVHD
(range)
5 months (2-21)
Type of presentation of CGVHD
De novo 10 (25%)
Quiescent 11 (27%)
Progressive 19 (48%)
Major organ involvement at diagnosis
of CGVHD
Skin 36 (90%)
Oral 18 (45%)
Liver 15 (38%)
Eye 9 (22%)
Gut 7 (17%)
DLI indicates donor lymphocyte infusion.
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chen planus-like histology, varying degrees of dermal lympho-
cyte inﬁltration with or without epithelial apoptotic elements,
and cryptitis. The diagnostic criteria we used for chronic GI
GVHD was devised by us because almost all the data about
chronic GI GVHD were based on autopsy studies that were
reported before there was early recognition and treatment of
chronic GVHD. Nonetheless, at least 2 histologic indicators of
chronic inﬂammation should be sufﬁcient to suggest the pres-
ence of chronic GVHD component in the intestinal lesions of
these patients.
There may be several plausible explanations for the relative
uncertainty and infrequency of chronic GI GVHD in this pa-
tient population. First, almost half of the study subjects in this
report had progressive onset of CGVHD. In this setting, it is
not surprising to observe ongoing acute GVHD features in GI
histology. Second, using deﬁnitions in the literature, diagnosing
chronic GI GVHD is difﬁcult. The symptoms are relatively
nonspeciﬁc, there are no speciﬁc endoscopic ﬁndings, and mu-
cosal biopsies may miss deep ﬁbrosis or inﬂammation. Autopsy
series have shown that the histologic hallmark of the presence of
an inﬂammatory process is usually located in the deep submu-
cosal and subserosal layers of the GI wall [5,6]. Although deeper
biopsy sampling may increase the yield of capturing chronic GI
GVHD, this is not an acceptable approach because of the po-
tential risks associated with it. Also, the optimum location for
obtaining a biopsy could be missed, and this may result in
underestimation of severity of GVHD or even missing the
diagnosis of GVHD. In a recent report, Ponec et al suggested
both the endoscopic evaluation and the histology of the upper
gut can underestimate the severity of acute GVHD elsewhere in
the intestine unless extensive mucosal sloughing is seen [11].
Finally, chronic GI GVHD may actually be rare. The GI symp-
toms of about one third of the patients in this study were caused
by something other than GVHD.
The diagnosis of GI involvement by GVHD requires ex-
tensive evaluation to rule out other causes of GI symptoms. In
Table 3. Description of 9 Cases with Possible Chronic GI GVHD
Case GI Symptoms
Major Endoscopic
Findings
Histologic Criteria
for GI GVHD Other Tests
Type of
GI GVHD
Time from CGVHD
to GI GVHD (mos)
1 Diarrhea Erythema (rectum) Crypt distortion, Paneth
cell metaplasia
No infection Possible chronic 11
2 Abdominal pain,
diarrhea, GI bleeding,
partial obstruction
Erythema, edema,
cobblestone, granular,
friable, mucosa and a
bleeding site
(duodenum), edema,
markedly friable
mucosa, erosions
(colon and rectum)
Crypt apoptosis, Crypt
distortion and drop
out, fibrosis
No infection
CT: thickened bowel
Definite acute and
possible chronic
0.7
3 Chronic diarrhea and
weight loss
Nonspecific findings
(stomach, duodenum,
colon and rectum)
Active chronic
inflammation, Paneth
cell metaplasia, crypt
distortion
No infection Possible chronic 12
4 Chronic diarrhea and
weight loss
Granular edematous
mucosa (duodenum,
jejunum), normal
(rectum)
Chronic inflammation,
villous blunting, focal
cryptitis scattered
apoptosis
No infection
CT: dilated featureless
small bowel.
Fecal fat: 10 g/day
Possible acute and
possible chronic
8
5 Nausea, vomiting and
diarrhea
No info—upper and
lower GI endoscopy
Focal epithelial cell
necrosis, lymphocyte
satellitosis, focal
apoptosis, crypt drop
out and distortion
CMV () Definite acute and
possible chronic
0
6 Rectal bleeding and
diarrhea
Mucosal granularity
(rectum), normal
(stomach and
duodenum)
Mucosal ulcers,
Crypt distortion,
Scarring of lamina
propria, lymphocyte
depletion of lamina
propria, occasional
apoptotic cells
No infection upper GI
series:
Multiple abnormal ileal
loops, featureless
small bowel, fine
nodularity, esophageal
spasm and delay in
transit to colon
Possible acute and
possible chronic
1
7 Nausea, vomiting,
diarrhea, GI bleeding
No info—lower GI
endoscopy
Apoptotic lesions, crypt
distortion and loss,
increased plasma cells
in lamina propria
(colon and rectum)
No infection
CT: thickened bowel
wall and ascitis
Definite acute and
possible chronic
0
8 Abdominal pain,
diarrhea, GI bleeding
No info—lower GI
endoscopy
Active inflammatory
disease, cryptitis and
crypt abscess,
scattered apoptosis,
crypt distortion
Scarring
No infection Definite acute
possible chronic
0
9 Diarrhea No info—lower GI
endoscopy
Fibrosis, crypt
distortion
No infection Possible chronic 27
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patients within a year of diagnosis of chronic GVHD, ongoing
acute GVHD and infection were the most common causes of the
GI symptoms. In patients more than a year from the original
diagnosis of chronic GVHD, drug-induced gastritis, GI dysmo-
tility, and pancreatic insufﬁciency responding to pancreatic en-
zyme replacement therapy were the most common causes of GI
symptoms, not GVHD. It is not clear whether motility disorders
are part of chronic GVHD because the histology in the majority
of these patients failed to show pathologic ﬁndings. In 7 patients
in this series, gastroparesis, esophageal spasm, and delay in
transit were found. Only 2 of these patients met the histologic
criteria for possible chronic GI GVHD. Gastroparesis was de-
scribed as a motility disorder after BMT. In a recent study, 14 of
18 patients who underwent BMT had delayed gastric emptying,
mostly responsive to prokinetic agents [12]. Nine of these pa-
tients were also evaluated with upper GI endoscopy. GVHD on
gastric biopsy was an uncommon ﬁnding and was mild when
present. Seven patients in the present study had GI motility
disorder with or without associated GI GVHD. Barium swallow
studies done in these patients demonstrated esophageal dysmo-
tility/spasm, overall delay in transit time, and gastroparesis.
Weight loss was one of the common symptoms associated
with chronic diarrhea in our patients. Although poor oral caloric
intake is certainly one of the possible causes of weight loss in
patients with CGVHD, it is not the only one. The cause of
weight loss remains obscure in some of these patients. In our
routine GVHD practice, we have seen many cachectic patients
despite adequate oral intake [13]. After ruling out an active
inﬂammatory process in the GI tract or a motility disorder,
increased expression and translation of various hormones and
cytokines (tumor necrosis factor-alpha) may be the cause of
weight loss in patients with chronic GVHD. A recent study
suggested that patients with chronic extensive GVHD show an
increase in resting energy expenditure and alterations in fat and
carbohydrate oxidation rates. These changes seemed to be the
result of increased action of glucagon and norepinephrine [14].
The role of TNF-alpha in the mechanism of weight loss in
chronic GVHD is not well known. In a murine study, transgenic
mice that overexpress TNF-alpha gene were created. These
mice had severe cachexia and skin changes that resembled
GVHD [15].
The other causes of GI symptoms as shown in this series
included drug side effect, infections, and gastroesophageal reﬂux
disease/gastritis. It is important to remember this differential
diagnosis because the symptoms quickly resolve when the un-
derlying causes are identiﬁed and eliminated. We diagnosed
malabsorption in 3 patients based on history, clinical ﬁndings,
and increased 24-hour fecal fat excretion. They responded well
to pancreatic enzyme replacement therapy with signiﬁcant im-
provement in their abdominal pain and diarrhea. As we reported
recently [16], pancreatic insufﬁciency should be in differential
diagnoses in patients with CGVHD who have had a longstand-
ing history of bulky, oily, and foul-smelling diarrhea.
Although we included a substantial number of patients who
were evaluated both clinically and pathologically in the present
study, we cannot state with certainty that the results are reﬂec-
tive of all patients with GI GVHD. Given the lack of consensus
in the deﬁnition of chronic GI GVHD, we believe our data will
provide important information on causes of GI symptoms in
late-posttransplantation patients. In conclusion, patients with
GI acute GVHD may have persistent acute GI GVHD even
though clinically their skin and other organs now appear to be
consistent with chronic GVHD. Patients with persistent acute
GI GVHD have a very poor prognosis. In this series, all died of
GVHD and its complications. Although chronic GVHD itself
may involve the GI tract, it is a rare phenomenon, is difﬁcult to
diagnose, and is seldom seen without simultaneous acute
GVHD.
REFERENCES
1. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-
versus-host syndrome in man. A long-term clinicopathologic study
of 20 Seattle patients. Am J Med. 1980;69:204-217.
2. Sale GE, McDonald GB, Shulman HM, Thomas ED. Gastrointes-
tinal graft-versus-host disease in man. Am J Surg Pathol. 1979;3:
291-299.
3. Ferrara JLM, Degg HJ. Graft vs host disease. N Engl J Med.
1991;324:667-674.
4. Sullivan KM. Graft versus host disease. In: Thomas ED, Blume KG,
Forman SJ, eds. Hematopoietic Stem Cell Transplantation. Cambridge,
Massachusetts: Blackwell Science; 1999:515-536.
5. Snover DC, Weisdorf SA, Vercelloti GM, Rank B, Hutton S,
McGlave P. A histopathologic study of gastric and small intestinal
GVHD following allogeneic BMT. Hum Pathol. 1985;16:387-392.
6. Snover DC. Graft-versus-host disease of the gastrointestinal tract.
Am J Surg Pathol. 1990;14:101-108.
7. Saurat JH, Gluckman E, Bussell A, Didierjean L, Puissant A. The
lichen planus-like eruption after bone marrow transplantation. Br J
Dermatol. 1975;93:675-681.
8. Farmer ER. The histopathology of graft-versus-host disease. Adv
Dermatol. 1986;1:173-188.
9. Vogelsang GB. How I treat chronic graft-versus-host disease. Blood.
2001;97:1196-1201.
10. Bombi J, Nadal A, Carreras E, et al. Assessment of histopathologic
changes in the colonic biopsy in acute graft-versus-host disease.
Am J Clin Pathol. 1995;103:690-695.
11. Ponec RJ, Hackman RC, McDonald GB. Endoscopic and histologic
diagnosis of intestinal graft-versus-host disease after marrow trans-
plantation. Gastrointest Endosc 1999;49:612-621.
12. Eagle DA, Gian V, Lauwers GY, et al. Gastroparesis following bone
marrow transplantation. Bone Marrow Transplant. 2001;28:59-62.
13. Jacobsohn DA, Margolis J, Doherty J, Anders V, Vogelsang GB.
Weight loss and malnutrition in patients with chronic graft-versus-
host disease. Bone Marrow Transplant. 2002;29:231-236.
14. Zauner C, Rabitsch W, Schneeweiss B, et al. Energy and substrate
metabolism in patients with chronic extensive graft-versus-host dis-
ease. Transplantation. 2001;71:524-528.
15. Cheng J, Turksen K, Yu QC, Schreiber H, Teng M, Fuchs E.
Cachexia and graft-vs.-host-disease–type skin changes in keratin
promoter-driven TNF alpha transgenic mice. Genes Dev 1992;6:
1444-1456.
16. Akpek G, Valladares JL, Lee L, Margolis J, Vogelsang GB. Pan-
creatic insufﬁciency in patients with chronic graft-versus-host dis-
ease. Bone Marrow Transplant 2001;27:163-166.
GI Involvement in cGVHD
51BB&MT
